Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 9,154 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Tibial Fractures
Interventions: reamed, interlocking intramedullary nail, locking periarticular plate; Device
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Davis, California • San Francisco, California + 22 more

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: SMS995, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Hematologic Neoplasms
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 19
States / cities: Duarte, California • Stanford, California • Aurora, Colorado + 14 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Membranous Nephropathy
Interventions: Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more

Conditions: Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Interventions: KIN-2787, KIN-2787 and binimetinib; Drug
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: Infertility
Interventions: Clomiphene Citrate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 1994
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions: Blood Collection, Blood Volume Analysis; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: anastrozole, exemestane, letrozole, sorafenib tosylate, placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Interventions: Quality-of-Life Assessment, Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan; Other · Biological · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Microscopic Colitis, Diarrhea
Interventions: Mesalamine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glioma, Glioblastoma Multiforme
Interventions: APG-157; Drug
Lead sponsor: Aveta Biomics, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
Interventions: TP-0903; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more

Conditions: Lymphoma
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 9 more

Conditions: Crohn's Disease
Interventions: Filgotinib, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 100
States / cities: Dothan, Alabama • Sun City, Arizona • Coronado, California + 80 more

Conditions: Malignant Pleural Mesothelioma
Interventions: defactinib (VS-6063), Placebo; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 5 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Epidural Spinal Cord Compression
Interventions: Surgical excision of the metastatic process, Radiotherapy of the metastatic spine process; Procedure · Radiation
Lead sponsor: AOSpine North America Research Network; Network
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 7
States / cities: Kansas City, Kansas • Baltimore, Maryland • Rochester, Minnesota + 3 more

Conditions: Crohn Disease
Interventions: Ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 190
States / cities: Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Multiple Myeloma
Interventions: Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 737 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 80 more

Conditions: Fibromyalgia
Interventions: Strength training, Aerobic exercise; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dysphagia
Interventions: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES); Device
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Evanston, Illinois + 8 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, cyclophosphamide, melphalan, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Proximal Tibial Fractures

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Is Our Microbiome a Predictor of Cardiac Risk

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Bone Health in Patients With Atopic Dermatitis

Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Exercise for Fibromyalgia

Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse